MedTrace Logo

Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin

NCT01823133 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-08-28

No results posted yet for this study

Summary

Investigate the pharmacokinetic drug interactions between gemigliptin and rosuvastatin in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

gemigliptin only

gemigliptin 50mg qd on day 1\~7

DRUG

rosuvastatin only

rosuvastatin 20mg qd on day 1\~7

DRUG

gemigliptin and rosuvastatin

gemigliptin 50mg, rosuvastatin 20mg qd on day 1\~7

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-05-31
Completion
2013-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01823133 on ClinicalTrials.gov